

Index

• A •

- AABB (Web site), 229
- abortion and stem cell research
 - genetic testing, relationship to, 247
 - induced-abortion fetuses as stem cell sources, 97, 255, 287
 - legal and policy issues, 234, 253, 255, 262
 - myths about, 287–288
 - religious views on, 237, 240, 244
- academic funding, 275–276
- accrediting agencies for cord blood banks, 229
- acquired characteristics in heredity, 41
- acute myeloid leukemia, 132
- adhesion molecule, 128
- adipose tissue, 81
- adult stem cells
 - abilities of, 74–77
 - about, 71
 - in bone marrow, 13–14, 78–81, 185
 - in brain, 81–82, 143
 - in cord blood, 84–85, 221–227, 331
 - defined, 17, 71, 72–74, 329
 - embryonic stem cells, compared to, 289
 - in heart, 82
 - identifying, 18
 - in intestines, 82
 - key properties, 17–18
 - limitations, 76–77
 - in lungs, 83
 - multipotent capability, 61, 71, 334
 - in pancreas, 83
 - quiescent, 74
 - in skin, 83
 - sources of, 77–84
 - tissue stem cells, compared to, 73
 - treatment successes, 292–293
 - uses, 76–77
 - working with, 85
 - workings of, 75–76
- adult-onset diabetes, 168–169
- Advanced Cell Technology, 113, 258
- adverse event reporting for stem cell research, 268
- age-related macular degeneration, 308
- allogeneic transplant, 206, 207
- ALS (amyotrophic lateral sclerosis), 66, 107, 145–149, 306–307, 329
- altered nuclear transfer (ANT), 91, 242, 329
- Alzheimer's disease
 - about, 138–139
 - clinical trials, 140–142
 - defined, 329
 - genetic causes, 141–142
 - progression of, 139–140
 - stem cell potential, 142–144
 - symptoms, 139
- American Society of Reproductive Medicine (Web site), 327
- amniotic stem cell, 329
- amyloid plaques in Alzheimer's, 139
- amyotrophic lateral sclerosis (ALS), 66, 107, 145–149, 306–307, 329
- anemia, 329
- angioplasty, 160
- animal regeneration, 39–40
- animal research
 - animal model defined, 329
 - chimeras, 105–106, 107, 118
 - cloning in, 50, 108–109
 - cybrids, 90, 104, 114–119, 331
 - hybrids, 102, 104
 - mouse's role in, 12–15, 142
- animal treatments, application to humans, 196
- ANT (altered nuclear transfer), 91, 242, 329
- antibodies, 64
- aperesis, 205
- apoptosis, 126, 329
- applied research, 256
- arrhythmia, 163
- assay, 79
- astrocyte, 24, 147, 329

asymmetric cell division, 23, 329
 autografting, 46
 autoimmune diseases, Natural Killer cell
 role in, 15
 autologous transplant, 186, 206, 207
 axon, 23, 330

• B •

Back to Sleep campaign for SIDS
 prevention, 244–245
 banking stem cells
 about, 221
 choosing a bank, 227–230
 cord-blood banking process, 222–227
 depositing into, 224–226
 future of, 230
 private compared to public storage,
 223–224, 225
 problems with, 226–227
 Baptist churches' viewpoint, 236
 basal cell carcinoma, 129
 basement membrane, 128
 basic research and innovation,
 256–258, 330
 Batten Disease, 149–150, 195
 BDNF growth factor, 152
 Be The Match Foundation (Web site),
 217, 326
 beneficence principle in research on
 humans, 260
 benign tumor, 128, 301
 beta cells, pancreatic, 26, 30, 83, 166
 bioethics issues. *See also* funding and
 profits; laws and policies
 abortion and stem cell research
 genetic testing, relationship to, 247
 induced-abortion fetuses as stem cell
 sources, 97, 255, 287
 legal and policy issues, 234, 253,
 255, 262
 myths about, 287–288
 religious views on, 237, 240, 244
 about, 1, 233–234
 ANT technique, 91, 242, 329
 chimeras, 242–243
 cloning, 242
 cooperation with evil problem, 239–241
 embryos created specifically for
 research, 241–242, 288–289
 eugenics, 245–246
 fetal tissue research, 243–245, 255–256
 genetic testing and manipulation, 245–247
 goals of stem cell research, 247–248
 human subject research, 260–261
 “living and human compared to living
 human” issue, 238–239
 national-level bioethics panels, 327–328
 personhood definitions, 234–239
 pluripotent alternatives to embryonic
 stem cells, 87–88
 religious viewpoints, 235–238, 240,
 244, 247
 research goals, relationship to, 247–248
 scientific community's self-policing,
 267–268
 SCNT technique, 89–91, 108–114, 242, 337
 selling of eggs problem, 241
 Warnock Commission viewpoint, 238
 biopsy, 131
 biotechnology industry, 272, 277–279
 blast crisis in leukemia, 131
 blastocyst
 defined, 13, 330
 development of, 55
 ethical issues, 88, 262
 germ layers
 defined, 333
 ectoderm, 56, 331
 embryoid bodies, 62, 332
 endoderm, 56, 282, 332
 mesoderm, 56, 334
 blood brain barrier, 195
 blood sources for stem cells
 bone marrow as stem cell source, 13–14,
 78–81, 185, 203–204
 cord blood
 about, 84–85
 banking of, 221–230
 defined, 331, 338
 medical uses, 221–222
 as stem cell source, 205

- blood-forming (hematopoietic) stem cells, 72, 78, 202, 333
 - body systems overview, 30–32
 - body wall, 128
 - bone marrow as stem cell source, 13–14, 78–81, 185, 203–204
 - brain diseases and conditions
 - cancer, 131
 - neurodegenerative diseases
 - about, 137–138
 - ALS (Lou Gehrig’s Disease), 66, 107, 145–149, 306–307, 329
 - Alzheimer’s disease, 138–144, 329
 - Batten Disease, 149–150, 195
 - cerebral palsy, 150–151
 - commonalities, 138
 - defined, 137
 - Huntington’s disease, 151–152, 306–307
 - Niemann-Pick Disease, 152–153, 335
 - Parkinson’s disease, 153–156, 306–307, 335
 - spinal cord injuries, 67, 156–157, 194–195, 306
 - stroke consequences, 157–158, 307
 - brain stem cells, 81–82, 143
 - Briggs, Robert (researcher), 88
 - Brown, Louise (first IVF baby), 49
 - Brownback, Sam (U.S. Senator), 119
 - Buddhist viewpoint, 236, 237
 - Bush, George W. (president), 251, 254, 263, 272, 294
- C ●
- cancer
 - basic progression of, 124–129
 - cancer stem cells, 96–97, 129–135
 - cell biology of, 23
 - cloning in research on, 108–109
 - collecting stem cells from tumors, 96–97
 - differences in cells, 132, 133
 - embryonal carcinoma cell, 96
 - genetic instruction changes, 125–126
 - history of treatment attempts, 123–124
 - living beyond normal lifespan, 127–128
 - metastasizing progress, 128–129
 - out-of-control growth problem, 126–127
 - teratocarcinoma, 96
 - treatments, 15, 130–131, 134–135, 187–188, 212, 303–304
 - types of, 131
 - cancers of unknown primary (CUP), 131
 - carcinogenic, defined, 124
 - carcinoma, 123, 131
 - cardiac muscle, 32
 - cardiomyocytes, 66
 - cardiovascular, defined, 161
 - catheter, 213
 - Catholic viewpoint, 235, 236, 240, 247
 - CDX2 gene, 329, 330
 - cell biology, basic
 - about, 21
 - building tissues and organs, 29–33
 - stem cells compared to other cells, 33–35
 - structure and function, 21–29
 - cell body, 23, 330
 - cell communication, 29
 - cell division, 22–23, 55, 329, 330, 337
 - cell line, 60
 - cell membrane, 330
 - cell replacement, 19, 24
 - cell suicide, 126
 - cell (cell-based) therapies
 - adult stem cell successes, 292–293
 - ALS (Lou Gehrig’s disease), 66, 107, 145–149, 306–307, 329
 - Alzheimer’s disease, 139, 140–144
 - animal treatments, applying
 - to humans, 196
 - assessment of, 187–192, 312–313, 317
 - Batten Disease, 149–150, 195
 - bone marrow transplants
 - for leukemia, 185
 - cancer
 - history of treatment attempts, 123–124
 - treatments, 15, 130–131, 134–135, 187–188, 212, 303–304
 - cerebral palsy, 150–151
 - development of, 313–314
 - diabetes, 166–169, 191–192, 309–310

- cell (cell-based) therapies (*continued*)
 - drug therapies
 - about, 171
 - ALS (Lou Gehrig's disease), 107, 146–147, 148–149
 - Alzheimer's disease, 139, 141–143
 - cancer treatment, 130–131, 134, 135
 - clinical trials' role, 174–175, 176, 177–178, 179
 - cost of development, 174–179
 - development process, 171–179
 - genetic origins for response
 - differences, 44
 - Huntington's disease, 152
 - for immune-suppression in transplant
 - cases, 46–47, 48–49, 210–211
 - insulin therapy using cloning
 - technique, 110
 - multiple sclerosis, 190
 - Niemann-Pick disease, 153
 - Parkinson's disease, 154, 155, 156
 - pros and cons of current, 172–174
 - regulation of, 178–179
 - safety and effectiveness, 176–178
 - stem cell role in, 68, 111, 179–180, 278–279, 290–291, 304–305
 - tolerance issue, 173
 - experimental, 314–315
 - expert opinions, 319
 - grafting skin to treat burns, 186–187
 - heart disease
 - challenges with stem cells, 163–164
 - clinical trials involving stem cells, 162–163, 189–190, 301–302
 - current treatment options, 160–161
 - stem cell treatment, 161–162, 189–190, 309
 - hidden costs, 318–319
 - Huntington's disease, 151–152, 306–307
 - independent oversight and regulation of
 - clinics, 312
 - informed consent issue, 319–320
 - liver disease, 159–160, 164–166
 - lupus, 192
 - multiple sclerosis, 190, 308
 - Niemann-Pick Disease, 152–153, 335
 - obstacles to, 295–302
 - Parkinson's disease, 153–156, 306–307, 335
 - patient testimonials, 317–318
 - replacement tissues, 305–306
 - reversing retinal degeneration, 308–309
 - risks and side effects, 315–317
 - scams and charlatans, 321–322
 - spinal cord injuries, 67, 156–157, 194–195, 306
 - as stem cell purpose, 19
 - stroke, 157–158, 307
- cells. *See also* stem cells
 - cancer, 23, 132, 133
 - common functions, 12
 - communication, 29, 63
 - culturing of, 330
 - differentiation, 16, 54, 55, 89, 331
 - diploid, 255
 - enucleated, 108, 332
 - eukaryotic, 12
 - feeder, 60, 332
 - genetic controls
 - changing instructions, 125–126
 - growth factors, 44–45
 - heredity, 41–42
 - identifying stem cells, 46–47
 - mapping genetic library, 44
 - RNA, 25, 42, 336
 - germ, 89, 255, 333
 - glial, 82, 333
 - immune system, 15
 - inner cell mass, 16, 57, 119, 331, 334
 - in Lou Gehrig's Disease, 147–148
 - mixing and matching. *See* mixing and matching cells
 - Natural Killer (NK), 15
 - oocyte (egg cell), 335
 - pancreatic, 26, 30, 83
 - photoreceptor, 309
 - progenitor, 14, 73, 127, 336
 - prokaryotic, 12
 - red blood, 204
 - rogue, 15
 - Schwann, 24, 336
 - sizing, 23–24
 - skin, 14–15

- specialized, 14
- stem cells compared to, 33–35
- stromal, 63
- suicide of, 126
- terminally differentiated cell, 130, 337
- transfer of materials, 25–29
- white blood, 204
- cell-swapping technology (cybrids), 114–119
- cerebellum, 153
- cerebral cortex, 152
- cerebral palsy, 150–151
- chimeras, 105–107, 118, 330
- chimeric animals, 105–106, 118
- chromosome, 25, 330
- chronic myeloid leukemia, 130
- circulatory system, 31
- Clinical Laboratory Improvement Amendments (CLIA), 228
- clinical trials
 - ALS treatments, 146, 147–149
 - Alzheimer's disease, 140–142
 - animal treatment potential
 - for humans, 196
 - Batten Disease, 150
 - cancer, 189
 - challenges of, 197–199
 - cost of, 301
 - defined, 330
 - design, 302
 - double-blind, 177, 292, 331
 - drug development, relationship to, 174–175, 176, 177–178, 179
 - heart disease, 162–163, 189–190, 301–302
 - NIH registry, 326
 - Parkinson's disease, 156–157
 - spinal cord injury, 67, 157, 194–195
- Clinton, Bill (president), 253, 254
- Clonaid (Web site), 113
- clone, defined, 330
- cloning
 - animals, 50, 108–109
 - defined, 108
 - ethical issues, 242
 - of humans, 113, 291
 - primates, difficulties of, 111–114
 - reproductive, 89–91, 108, 242, 336, 337
 - research-related, 111
 - therapeutic, 108–109, 111, 337
- Cohen, Stanley (researcher), 44
- Cole-Turner, Ronald (clergy), 119
- communication, cell, 29, 63
- conception
 - defined, 332
 - in vitro fertilization (IVF)
 - blastocyst creation role, 57
 - defined, 49, 57, 333
 - development of, 49–50
 - genetic testing, relationship to, 93
 - in vivo fertilization, 333
 - zygote, 55, 338
- conditioning prior to bone marrow transplant, 214
- cones (photoreceptor cell), 309
- connective tissue, 30
- conservation, gene, 12
- continuity of species, 41
- cord blood
 - about, 84–85
 - banking of
 - about, 221
 - banking process, 222–227
 - choosing a bank, 227–230
 - depositing into, 224–226
 - private compared to public storage, 223–224, 225
 - problems with, 226–227
 - defined, 331, 338
 - medical uses, 221–222
 - as stem cell source, 205
- coronary heart (artery) disease
 - about, 159–160
 - challenges with stem cells, 163–164
 - clinical trials involving stem cells, 162–163, 189–190, 301–302
 - current treatment options, 160–161
 - definitions, 161
 - prevalence, 160
 - risk factors, 160
 - stem cell treatment, 161–162, 189–190, 309
- Crick, Francis (researcher), 43

crypts (intestinal crevasses), 82
 culture medium, 59, 331
 culturing, 13
 CUP (cancers of unknown primary), 131
 C.W. Bill Young Cell Transplantation Program, 326
 cybrid (cytoplasmic hybrid), 90, 104, 114–119, 331
 cytoplasm, 21, 90, 111
 cytoplasmic hybrid (cybrid), 90, 104, 114–119, 331
 cytoplasmic transfer, 115



deep brain stimulation (DBS), 155
 delivery agent, stem cell as, 19
 dendrite, 23, 331
 deoxyribonucleic acid (DNA)
 about, 25, 42–43
 defined, 22, 25, 331
 mitochondrial, 88, 114
 recombinant, 110, 336
 derivation of stem cell line, 16, 331
 design patent, 280
 designated proxies, 177
 diabetes, 166–169, 191–192, 309–310
 Dickey-Wicker Amendment, 254, 255
 differentiation, cell, 16, 54, 55, 89, 331
 diffusible signals in cell communication, 29
 digestive system, 31
 diploid cell, 255
 directed differentiation, 331
 diseases
 ALS (Lou Gehrig's disease), 66, 107, 145–149, 306–307, 329
 Alzheimer's
 about, 138–139
 clinical trials, 140–142
 defined, 329
 genetic causes, 141–142
 progression of, 139–140
 stem cell potential, 142–144
 symptoms, 139
 Batten Disease, 149–150, 195

cancer
 basic progression of, 124–129
 cancer stem cells, 96–97, 129–135
 cell biology of, 23
 cloning in research on, 108–109
 collecting stem cells from tumors, 96–97
 differences in cells, 132, 133
 embryonal carcinoma cell, 96
 genetic instruction changes, 125–126
 history of treatment attempts, 123–124
 living beyond normal lifespan, 127–128
 metastasizing progress, 128–129
 out-of-control growth problem, 126–127
 teratocarcinoma, 96
 treatments, 15, 130–131, 134–135, 187–188, 212, 303–304
 types of, 131
 diabetes, 166–169, 191–192, 309–310
 heart disease
 about, 159–160
 challenges with stem cells, 163–164
 clinical trials involving stem cells, 162–163, 189–190, 301–302
 current treatment options, 160–161
 definitions, 161
 prevalence, 160
 risk factors, 160
 stem cell treatment, 161–162, 189–190, 309
 Huntington's disease, 151–152, 306–307
 liver disease, 159–160, 164–166
 lupus, 192
 multiple sclerosis, 190, 308
 Niemann-Pick Disease, 152–153, 335
 Parkinson's, 153–156, 306–307, 335
 distributed tissue, 77
 division, cell, 22–23, 55, 329, 330, 337
 DNA (deoxyribonucleic acid)
 about, 25, 42–43
 defined, 22, 25, 331
 mitochondrial, 88, 114
 recombinant, 110, 336
 Dolly the sheep, 50
 dominant gene, 247
 donating stem cells and/or organs/tissues, 206–210, 215–218

dopamine, 63, 154
 double helix, 43
 double-blind clinical trials, 177, 292, 331
 drug therapies
 about, 171
 ALS (Lou Gehrig's disease), 107, 146–147, 148–149
 Alzheimer's disease, 139, 141–143
 cancer treatment, 130–131, 134, 135
 clinical trials' role, 174–179
 cost of development, 174–179
 development process, 171–179
 genetic origins for response
 differences, 44
 Huntington's disease, 152
 for immune-suppression in transplant
 cases, 46–47, 48–49, 210–211
 insulin therapy using cloning
 technique, 110
 multiple sclerosis, 190
 Niemann-Pick disease, 153
 Parkinson's disease, 154, 155, 156
 pros and cons of current, 172–174
 regulation of, 178–179
 safety and effectiveness, 176–178
 stem cell role in, 68, 111, 179–180, 278–279, 290–291, 304–305
 tolerance issue, 173
 drug-like chemicals, finding, 175–176

● E ●

early onset Alzheimer's, 141
 EC (embryonal carcinoma) cell, 96
 ectoderm, 56, 331
 ectopic pregnancy, 244
 egg donation, 241
 electrical signals in cell communication, 29
 embryo. *See also* blastocyst
 creation specifically for research,
 241–242, 288–289
 defined, 54, 332
 fetus, compared to, 2, 238, 332
 in lab research, 258
 nuclear transfer techniques, 91–93
 stages of development, 54–56
 embryoid bodies, 62, 332
 embryonal carcinoma (EC) cell, 96
 embryonic germ cell, 97
 embryonic stem cell line, 289–290, 332
 embryonic stem cells
 about, 13, 53
 adult stem cells, compared to, 289
 defined, 33, 54, 332
 growing, 57–62, 64–65
 identifying, 18
 limitations, 68–70
 making cells and tissues, 62–65
 possibilities, 68–70
 pre-implantation, 336
 properties, 16–17, 59–62
 research issues, 65–68, 253–254, 293, 294
 stages of embryonic development, 54–56
 endocardium, 30
 endocrine system, 31
 endoderm, 56, 282, 332
 endothelial stem cells, 78
 Energy, Department of, 259
 ensoulment, 235
 enucleated cell, 108, 332
 epicardium, 30
 epidermal growth factor, 44
 epigenome, 45
 Episcopal Church's viewpoint, 236
 epithelial tissue, 30, 131
 ethical issues. *See also* funding and profits;
 laws and policies
 abortion and stem cell research
 genetic testing, relationship to, 247
 induced-abortion fetuses as stem cell
 sources, 97, 255, 287
 legal and policy issues, 234,
 253, 255, 262
 myths about, 287–288
 religious views on, 237, 240, 244
 about, 1, 233–234
 ANT technique, 91, 242, 329
 chimeras, 242–243
 cloning, 242
 cooperation with evil problem, 239–241

- embryos created specifically for
 - research, 241–242, 288–289
 - eugenics, 245–246
 - fetal tissue research, 243–245, 255–256
 - genetic testing and manipulation, 245–247
 - goals of stem cell research, 247–248
 - human subject research, 260–261
 - “living and human compared to living human” issue, 238–239
 - national-level bioethics panels, 327–328
 - personhood definitions, 234–239
 - pluripotent alternatives to embryonic stem cells, 87–88
 - religious viewpoints, 235–238, 240, 244, 247
 - research goals, relationship to, 247–248
 - scientific community’s self-policing, 267–268
 - SCNT technique, 89–91, 108–114, 242, 337
 - selling of eggs problem, 241
 - Warnock Commission viewpoint, 238
 - Ethics Advisory Board, 253
 - eugenics, 245–246
 - eukaryotic cell, 12
 - European Patent Office (EPO), 280
 - excretory system, 32
 - exit strategies for manipulated stem cells, 300
 - experimental treatments, 314–315
 - expert opinion, 319
- **F** ●
- FACS (fluorescent-activated cell sorter), 64, 332
 - FACT (Foundation for the Accreditation of Cellular Therapy) (Web site), 229
 - family cord blood bank, 223
 - FDA (Food and Drug Administration), 178, 222, 228, 259
 - federal government and stem cell research
 - about, 251–252
 - basic research and innovation
 - encouragement, 256–258
 - clinical trials registry at NIH, 326
 - cord blood banking practices, 228
 - ethical issues, relationship to, 239, 243, 244
 - funding role
 - agency sources of, 252–253
 - benefits for stem cell research, 274
 - Bush administration rules, 251, 254, 263, 272, 294
 - pro and con arguments on, 273–274
 - regulation in U.S., relationship to, 251–252, 253–256
 - research-only embryos, restriction against, 243
 - U.S. system, 269–270, 271–272
 - political pressures, 262–264
 - regulation role, 251–252, 253–256, 258–261, 288
 - feeder cell, 60, 332
 - fertilization
 - defined, 332
 - in vitro fertilization (IVF)
 - blastocyst creation role, 57
 - defined, 49, 57, 333
 - development of, 49–50
 - genetic testing, relationship to, 93
 - in vivo fertilization, 333
 - zygote, 55, 338
 - fetal tissue research, 243–245, 255–256
 - fetus
 - defined, 332
 - embryo, compared to, 2, 238, 332
 - induced-abortion fetuses as stem cell sources, 97, 255, 287
 - stem cells, relationship to, 287–288
 - viability question, 57
 - fight or flight response, 32
 - flow cytometer, 135
 - fluorescent-activated cell sorter (FACS), 64, 332
 - fMRI (functional magnetic resonance imaging), 138
 - Food and Drug Administration (FDA), 178, 222, 228, 259
 - Foundation for the Accreditation of Cellular Therapy (FACT) (Web site), 229

Franklin, Rosalind (researcher), 43
 full-body donation, 217
 functional magnetic resonance imaging (fMRI), 138
 funding and profits
 about, 269
 government funding role
 agency sources of, 252–253
 benefits for stem cell research, 274
 Bush administration rules, 251, 254, 263, 272, 294
 pro and con arguments on, 273–274
 regulation in U.S., relationship to, 251–252, 253–256
 research-only embryos, restriction against, 243
 U.S. system, 269–270, 271–272
 patents and licenses, 279–283
 private sector role
 academia, 275–276
 argument for, 273
 corporations, 258, 277–279, 291–292
 nonprofit foundations, 276–277

• G •

gamete, 89, 255, 333
 gastrula, 55
 gene conservation, 12
 gene therapy, 209
 genes
 CDX2, 329, 330
 cell control role
 DNA. *See* DNA
 growth factor, 44–45
 heredity, 41–42
 identifying stem cells, 46–47
 mapping genetic library, 44
 RNA, 25, 42, 336
 defined, 332
 as disease agents, 125–126, 141–142, 148, 151
 master, 19
 mutation of, 104, 151, 334
 tumor suppressor, 126, 338

genetic testing and manipulation, 93–94, 245–247
 genome, 25, 44, 45, 332
 germ cell, 89, 255, 333
 germ layers of blastocyst
 defined, 333
 ectoderm, 56, 331
 embryoid bodies, 62, 332
 endoderm, 56, 282, 332
 mesoderm, 56, 334
 germ plasm concept, 41
 Geron, 67, 157, 194–195
 glaucoma, 308
 Gleevec, 131
 glial cells, 82, 333
 global attitudes about stem cell research, 266–267
 glucose, 166
 glutamate, 146
 glycogen, 164
 gonads, 96
 good manufacturing practice (GMP), 296
 governmental role in stem cell research
 See also federal government and stem cell research
 international attitudes about stem cell research, 266–268
 state level, 228–229, 264–265, 272
 grafting skin to treat burns, 186–187
 graft-versus-host disease
 controlling, 211, 304
 defined, 333
 donor-recipient match for transplants, relationship to, 206
 function in transplants, 48, 185
 growth factors, 44–45, 75, 152, 333
 growth medium for embryonic stem cells, 59
 Gurdon, John (researcher), 50, 89

• H •

Harvard Stem Cell Institute (Web site), 325
 harvesting stem cells from bloodstream, 204–205

- Heap, Brian (researcher), 119
- heart, tissue layers of, 30
- heart disease
- about, 159–160
 - challenges with stem cells, 163–164
 - clinical trials involving stem cells, 162–163, 189–190, 301–302
 - current treatment options, 160–161
 - definitions, 161
 - prevalence, 160
 - risk factors, 160
 - stem cell treatment, 161–162, 189–190, 309
- heart stem cells, 82
- healthcare delivery, 302
- helix, 43
- hematopoiesis, 204
- hematopoietic (blood-forming) stem cells, 72, 78, 202, 333
- hemoglobin, 164, 209
- hemophilia, 93
- hemorrhagic stroke, 157
- hepatocyte, 73
- hereditary anemia, 329
- hereditary disease, 333
- heredity, 41–42. *See also* genes
- HGP (Human Genome Project), 45
- Hindu viewpoint, 237
- hippocampus, 81
- histones, 42
- history of stem cell research
- about, 37
 - cloning animals, 50
 - genetic controls in cells, 41–46
 - regeneration of body parts, 38–40
 - transplanting organs and tissues, 46–49
 - in vitro fertilization, 49–50
- HLA (human leukocyte antigen), 209
- homing markers, 80, 163
- Hooke, Robert (scientist), 41
- hormone replacement therapy (HRT), 199
- human chimeras, 106–107
- human cloning, 113, 291
- human compared to yeast cells, 12
- human embryonic stem cells
- about, 13, 53
 - adult stem cells, compared to, 289
 - defined, 33, 54, 332
 - growing, 57–62, 64–65
 - identifying, 18
 - limitations, 68–70
 - making cells and tissues, 62–65
 - possibilities, 68–70
 - pre-implantation, 336
 - properties, 16–17, 59–62
 - research issues, 65–68, 253–254, 293, 294
 - stages of embryonic development, 54–56
- Human Genome Project (HGP), 45
- human leukocyte antigen (HLA), 209
- human subjects, regulation of research on, 259–261
- human-animal hybrid myth, 104, 247
- humanzees, 247
- Huntingtin gene, 151
- Huntington's disease, 151–152, 306–307
- Hwang Woo-suk (researcher), 113
- hybrid vigor, 104
- hybridization, 102
- hybrids
- animal, 102–104
 - cytoplasmic hybrid (cybrid), 90, 104, 114–119, 331
 - defined, 101, 102, 333
 - human-animal hybrid myth, 104, 247
 - plants, 104
- hydra, defined, 39
- *I* ●
- illnesses
- ALS (Lou Gehrig's disease), 66, 107, 145–149, 306–307, 329
 - Alzheimer's
 - about, 138–139
 - clinical trials, 140–142
 - defined, 329
 - genetic causes, 141–142
 - progression of, 139–140
 - stem cell potential, 142–144
 - symptoms, 139
 - Batten Disease, 149–150, 195
 - cancer
 - basic progression of, 124–129
 - cancer stem cells, 96–97, 129–135
 - cell biology of, 23

- cloning in research on, 108–109
 - collecting stem cells from tumors, 96–97
 - differences in cells, 132, 133
 - embryonal carcinoma cell, 96
 - genetic instruction changes, 125–126
 - history of treatment attempts, 123–124
 - living beyond normal lifespan, 127–128
 - metastasizing progress, 128–129
 - out-of-control growth problem, 126–127
 - teratocarcinoma, 96
 - treatments, 15, 130–131, 134–135, 187–188, 212, 303–304
 - types of, 131
 - diabetes, 166–169, 191–192, 309–310
 - heart disease
 - about, 159–160
 - challenges with stem cells, 163–164
 - clinical trials involving stem cells, 162–163, 189–190, 301–302
 - current treatment options, 160–161
 - definitions, 161
 - prevalence, 160
 - risk factors, 160
 - stem cell treatment, 161–162, 189–190, 309
 - Huntington's disease, 151–152, 306–307
 - liver disease, 159–160, 164–166
 - lupus, 192
 - multiple sclerosis, 190, 308
 - Niemann-Pick Disease, 152–153, 335
 - Parkinson's, 153–156, 306–307, 335
 - immune response, overcoming, 46–47, 48–49, 210–211
 - immune system cells, 15
 - immune/lymphatic system, 32
 - implantation, 333
 - in vitro fertilization (IVF)
 - blastocyst creation role, 57
 - defined, 49, 57, 333
 - development of, 49–50
 - genetic testing, relationship to, 93
 - in vivo fertilization, 333
 - independent review guidelines for stem cell research, 267
 - induced pluripotent stem cells, 98, 333
 - informed consent, 177, 225, 259, 267, 319–320
 - inner cell mass, 16, 57, 119, 331, 334
 - innovation, 188, 256–258, 330, 334
 - international attitudes about stem cell research, 266–268
 - International Organization for Standardization (ISO) (Web site), 229
 - International Society for Science and Religion, 119
 - International Society for Stem Cell Research (ISSCR) (Web site), 266, 267–268, 325
 - intestinal stem cells, 82
 - ischemic stroke, 157
 - Islamic viewpoint, 236
 - islets, 30, 166, 191
 - ISO (International Organization for Standardization) (Web site), 229
 - ISSCR (International Society for Stem Cell Research) (Web site), 266, 267–268, 325
- *J* •
- Jewish Chronic Disease Hospital cancer study, 260
 - Jewish viewpoint, 236, 237
 - Jones Institute, 258
 - juvenile diabetes, 167–168, 191–192
- *K* •
- karyotyping, 60
 - King, Thomas (researcher), 88
 - Kinney, Hannah (researcher), 244–245
- *L* •
- Lamarck, Jean-Baptiste (naturalist), 41
 - Lao Tzu (philosopher), 20
 - laws and policies
 - abortion, 234, 253, 255, 262
 - about, 249–250
 - drug therapy regulation, 178–179
 - human subjects, research on, 259–261
 - in other countries, 266–267
 - patents and licenses, 279–283
 - political pressures, 262–264
 - research regulation and funding

- laws and policies (*continued*)
 - about, 251–252
 - basic research and innovation
 - encouragement, 256–258
 - funding role, 252–256
 - restrictions on questionable practices, 259–261
 - safety regulation, 258–259
 - scientific and medical societies, 267–268
 - state laws, 228–229, 264–265
 - leukemia, 131, 132
 - Levi-Montalcini, Rita (researcher), 44
 - licenses and patents, 279–283
 - lipids, 152
 - lipoproteins, 28
 - liver disease, 159–160, 164–166
 - “living and human compared to living human” issue, 238–239
 - Lou Gehrig’s disease (ALS), 66, 107, 145–149, 306–307, 329
 - lung stem cells, 83
 - lupus, 192
 - Lutheran churches’ viewpoint, 236
 - lymphatic/immune system, 32
 - lymphoma, 131
 - lysosomal storage disease, 149–150, 195, 334, 335
 - lysosome, 149, 195, 334
- M •**
- macula, 308
 - macular degeneration, 308
 - mapping genetic library, 44
 - markers, stem cell, 80, 163
 - master genes, 19
 - McCulloch, Ernest (researcher), 13–14, 46, 47, 79
 - mechanical injury, 157
 - mechanical signals in cell
 - communication, 29
 - mediate animation, 235
 - Medical News Today (Web site), 328
 - medical societies, 267–268
 - medical tourism, 311
 - medications (drug therapies)
 - about, 171
 - ALS (Lou Gehrig’s disease), 107, 146–147, 148–149
 - Alzheimer’s disease, 139, 141–143
 - cancer treatment, 130–131, 134, 135
 - clinical trials’ role, 174–179
 - cost of development, 174–179
 - development process, 171–179
 - genetic origins for response
 - differences, 44
 - Huntington’s disease, 152
 - for immune-suppression in transplant
 - cases, 46–47, 48–49, 210–211
 - insulin therapy using cloning
 - technique, 110
 - multiple sclerosis, 190
 - Niemann-Pick disease, 153
 - Parkinson’s disease, 154, 155, 156
 - pros and cons of current, 172–174
 - regulation of, 178–179
 - safety and effectiveness, 176–178
 - stem cell role in, 68, 111, 179–180, 278–279, 290–291, 304–305
 - tolerance issue, 173
 - membrane, cell, 22, 330
 - mesenchymal stem cells, 49, 78, 81, 88, 334
 - mesoderm, 56, 334
 - mesothelioma, 129
 - metastasis, 185
 - metastasize, defined, 128
 - Methodist churches’ viewpoint, 236
 - microglia, 147
 - microns, 23
 - Miescher, Friedrich (biologist), 42
 - mitochondria, 22, 111, 115, 334
 - mitochondrial DNA, 88, 114
 - mixing and matching cells
 - about, 101–102
 - cell-swapping technology, 117–119
 - chimeras, 105–107, 118, 330
 - cloning
 - animals, 50, 108–109
 - defined, 108
 - ethical issues, 242
 - of humans, 113, 291

- primates, difficulties of, 111–114
 reproductive, 89–91, 108, 242, 336, 337
 research-related, 111
 therapeutic, 108–109, 111, 337
 cybrids, 90, 104, 114–119, 331
 hybrids
 animal, 102–104
 cytoplasmic hybrid (cybrid), 90, 104,
 114–119, 331
 defined, 101, 102, 333
 human-animal hybrid myth, 104, 247
 plants, 104
 mobilized blood, 185
 moral issues. *See also* funding and profits;
 laws and policies
 abortion and stem cell research
 genetic testing, relationship to, 247
 induced-abortion fetuses as stem cell
 sources, 97, 255, 287
 legal and policy issues, 234, 253,
 255, 262
 myths about, 287–288
 religious views on, 237, 240, 244
 about, 1, 233–234
 ANT technique, 91, 242, 329
 chimeras, 242–243
 cloning, 242
 cooperation with evil problem, 239–241
 embryos created specifically for
 research, 241–242, 288–289
 eugenics, 245–246
 fetal tissue research, 243–245, 255–256
 genetic testing and manipulation, 245–247
 goals of stem cell research, 247–248
 human subject research, 260–261
 “living and human compared to living
 human” issue, 238–239
 national-level bioethics panels, 327–328
 personhood definitions, 234–239
 pluripotent alternatives to embryonic
 stem cells, 87–88
 religious viewpoints, 235–238, 240,
 244, 247
 research goals, relationship to, 247–248
 scientific community’s self-policing,
 267–268
 SCNT technique, 89–91, 108–114, 242, 337
 selling of eggs problem, 241
 Warnock Commission viewpoint, 238
 morphology, 132, 334
 motor neuron, 19, 23, 63, 334
 mouse’s research role, 12–15, 142
 multiple sclerosis (MS), 190, 308
 multipotent stem cells, 61, 71, 329, 334
 Murray, Joseph, 46, 47
 muscle tissue, 30
 muscular system, 32
 mutation, gene, 104, 151, 334
 myelin sheath
 defined, 334
 function of, 24
 multiple sclerosis, relationship to, 190
 spinal cord injuries, relationship to,
 67, 156
 stem cell repair of, 35, 67
 myeloablation, 214
 myeloma, 131
 myocardium, 30
 myths, stem cell, 287–294
- N •
- Namenda, 139
 nanometers, 42
 National Academies (Web site), 267,
 323–324
 National Academy of Sciences (Web site),
 243, 323–324
 National Bioethics Advisory Commission,
 243, 254
 National Bone Marrow Program
 (Web site), 326
 National Cancer Institute (Web site), 324
 National Commission for the Protection
 of Human Subjects of Biomedical and
 Behavioral Research, 260
 National Council of Churches, 236
 National Heart, Lung, and Blood Institute
 (Web site), 324
 National Human Genome Research
 Institute (Web site), 324

- National Institute of Diabetes and Digestive and Kidney Diseases (Web site), 324
- National Institute of Neurological Disorders and Stroke (Web site), 324
- National Institutes of Health (NIH)
- clinical trials registry, 326
 - funding for stem cell research, 252, 254, 271
 - guidelines for stem cell research, 251
 - regulation of stem cell research, 259
 - Web site, 324
- National Marrow Donor Program (Web site), 215, 217
- National Research Act (1974), 260
- National Science Foundation (NSF), 250, 252
- national-level bioethics panels, 327–328
- Natural Killer (NK) cells, 15
- nerve growth factor, 44, 152
- nerve tissue, 20
- nervous system, 32
- neurodegenerative diseases and conditions
- about, 137–138
 - ALS (Lou Gehrig’s Disease), 66, 107, 145–149, 306–307, 329
 - Alzheimer’s disease, 138–144, 329
 - Batten Disease, 149–150, 195
 - cerebral palsy, 150–151
 - commonalities, 138
 - defined, 137
 - Huntington’s disease, 151–152, 306–307
 - Niemann-Pick Disease, 152–153, 335
 - Parkinson’s disease, 153–156, 306–307, 335
 - spinal cord injuries, 67, 156–157, 194–195, 306
 - stroke consequences, 157–158, 307
- neurofibrillary tangles (NFTs) in Alzheimer’s, 139
- neuronal stem cell, 142, 150, 335
- neurons
- defined, 59, 335
 - motor, 19, 23, 63
 - sensory, 23
- neurotransmitter, 154, 335
- NFTs (neurofibrillary tangles) in Alzheimer’s, 139
- niche, stem cell, 20, 335
- Niemann-Pick Disease, 152–153, 335
- NIH (National Institutes of Health)
- clinical trials registry, 326
 - funding for stem cell research, 252, 254, 271
 - guidelines for stem cell research, 251
 - regulation of stem cell research, 259
 - Web site, 324
- NK (Natural Killer) cells, 15
- Nobel Foundation (Web site), 327
- nongenetic ALS, 148
- nuclear transfer techniques
- ANT (altered nuclear transfer), 91, 242, 329
 - defined, 88
 - embryo development, 91–93
 - SCNT (somatic cell nuclear transfer), 89–91, 108–114, 242, 337
- nuclei, 42, 335
- nuclein, 42
- nucleoid region, 12
- nucleus, 21, 335
- Nuremberg Code, 259
- nutritional counseling for ALS, 146



- Obama, Barack (president), 251, 254
- Occupational Safety and Health Administration (OSHA), 258
- OCT-4 protein, 18
- olfactory bulb, 81
- oligodendrocyte, 24, 67, 194, 335
- oocyte (egg cell), 335
- open-label trial, 315
- organ damage, 173
- organ systems, 30
- organelle, 22
- OSHA (Occupational Safety and Health Administration), 258

• p •

- pancreatic beta cells, 26
 pancreatic cells, 30
 pancreatic diseases, 159–160, 166–169, 309–310
 pancreatic stem cells, 83
 pancreatitis, 166
 Parkinson's Disease, 153–156, 306–307, 335
 parthenogenesis, 94–96, 335
 passage in subculturing of stem cells, 60
 patent thicket, 279, 282
 patents and licenses, 279–283
 patient testimonials, 317–318
 penumbra, stroke, 158
 personhood, beginning of, 234–238
 PGD (pre-implantation genetic diagnosis), 93–94
 pharmaceutical companies, 174–175, 177, 274, 279, 283
 PharmaStem licensing, 227
 philosophical issues. *See also* funding and profits; laws and policies
 abortion and stem cell research
 genetic testing, relationship to, 247
 induced-abortion fetuses as stem cell sources, 97, 255, 287
 legal and policy issues, 234, 253, 255, 262
 myths about, 287–288
 religious views on, 237, 240, 244
 about, 1, 233–234
 ANT technique, 91, 242, 329
 chimeras, 242–243
 cloning, 242
 cooperation with evil problem, 239–241
 embryos created specifically for research, 241–242, 288–289
 eugenics, 245–246
 fetal tissue research, 243–245, 255–256
 genetic testing and manipulation, 245–247
 goals of stem cell research, 247–248
 human subject research, 260–261
 “living and human compared to living human” issue, 238–239
 national-level bioethics panels, 327–328
 personhood definitions, 234–239
 pluripotent alternatives to embryonic stem cells, 87–88
 religious viewpoints, 235–238, 240, 244, 247
 research goals, relationship to, 247–248
 scientific community's self-policing, 267–268
 SCNT technique, 89–91, 108–114, 242, 337
 selling of eggs problem, 241
 Warnock Commission viewpoint, 238
 photoreceptor cells, 309
 physical therapy for ALS, 146
 Pittsburgh compound B, 140
 placebo, 177, 335
 placebo effect, 317, 335
 placenta, 61, 91, 335
 plant hybrid, 104
 plant patent, 280
 plasticity (transdifferentiation), 17–18, 338
 platelets, 127, 204, 336
 pluripotent stem cells
 defined, 61, 87, 333, 336
 engineering of, 98–99
 generating, 93–96
 reproductive sources, 97
 from tumors, 96–97
 polarized light, 112
 policies and laws
 abortion, 234, 253, 255, 262
 about, 249–250
 drug therapy regulation, 178–179
 human subjects, research on, 259–261
 in other countries, 266–267
 patents and licenses, 279–283
 political pressures, 262–264
 research regulation and funding
 about, 251–252
 basic research and innovation encouragement, 256–258
 funding role, 252–256
 restrictions on questionable practices, 259–261
 safety regulation, 258–259
 scientific and medical societies, 267–268
 state laws, 228–229, 264–265
 politics of stem cell research, 262–264
 prediabetic, defined, 168
 pre-implantation embryonic stem cell, 336

- pre-implantation genetic diagnosis (PGD), 93–94
- Presbyterian churches' viewpoint, 236
- President's Council on Bioethics (Web site), 328
- primitive streak, 119, 238, 262, 336
- primordial germ cell, 96, 97
- private compared to public cord blood banks, 223–224
- private sector and stem cell research
 - academic funding, 275–276
 - argument for support from, 273
 - corporate funding, 258, 277–279, 291–292
 - nonprofit foundation funding, 276–277
- profits and funding
 - about, 269
 - government funding role
 - agency sources of, 252–253
 - benefits for stem cell research, 274
 - Bush administration rules, 251, 254, 263, 272, 294
 - pro and con arguments on, 273–274
 - regulation in U.S., relationship to, 251–252, 253–256
 - research-only embryos, restriction against, 243
 - U.S. system, 269–270, 271–272
 - patents and licenses, 279–283
 - private sector role
 - academia, 275–276
 - argument for, 273
 - corporations, 258, 277–279, 291–292
 - nonprofit foundations, 276–277
- progenitor cell, 14, 73, 127, 336
- prokaryotic cell, 12
- protein, OCT-4, 18
- protein isolation, 14
- Protestant churches' viewpoint, 236, 237
- public bank donations, 225
- public sector role in stem cell research. *See also* federal government and stem cell research
 - international attitudes about stem cell research, 266–268
 - state level, 228–229, 264–265, 272
- pulse generator, 155
- quickenings, 234
- quiescence, 304
- quiescent adult stem cell, 74

• Q •

- quickenings, 234
- quiescence, 304
- quiescent adult stem cell, 74

• R •

- rabbit eggs as growth medium for stem cells, 118
- radical mastectomy, 125
- Raelian religious sect, 113
- randomized clinical trial, 315
- reach-through royalty provision, 282
- reactive oxygen species, 133
- receptor sites, 28
- recombinant DNA, 110, 336
- red blood cells, 204
- red marrow, 203
- regeneration of body parts, 38–40
- regenerative medicine
 - adult stem cell successes, 292–293
 - ALS (Lou Gehrig's disease), 66, 107, 145–149, 306–307, 329
 - Alzheimer's disease, 139, 140–144
 - animal treatments, applying to humans, 196
 - assessment of, 187–192, 312–313, 317
 - Batten Disease, 149–150, 195
 - bone marrow transplants for leukemia, 185
 - cancer
 - history of treatment attempts, 123–124
 - treatments, 15, 130–131, 134–135, 187–188, 212, 303–304
 - cerebral palsy, 150–151
 - development of, 313–314
 - diabetes, 166–169, 191–192, 309–310
 - drug therapies
 - about, 171
 - ALS (Lou Gehrig's disease), 107, 146–149
 - Alzheimer's disease, 139, 141–143
 - cancer treatment, 130–131, 134, 135

- clinical trials' role, 174–175, 176, 177–178, 179
- cost of development, 174–179
- development process, 171–179
- genetic origins for response
 - differences, 44
- Huntington's disease, 152
- for immune-suppression in transplant cases, 46–47, 48–49, 210–211
- insulin therapy using cloning technique, 110
- multiple sclerosis, 190
- Niemann-Pick disease, 153
- Parkinson's disease, 154, 155, 156
- pros and cons of current, 172–174
- regulation of, 178–179
- safety and effectiveness, 176–178
- stem cell role in, 68, 111, 179–180, 278–279, 290–291, 304–305
- tolerance issue, 173
- experimental, 314–315
- expert opinions, 319
- grafting skin to treat burns, 186–187
- heart disease
 - challenges with stem cells, 163–164
 - clinical trials involving stem cells, 162–163, 189–190, 301–302
 - current treatment options, 160–161
 - stem cell treatment, 161–162, 189–190, 309
- hidden costs, 318–319
- Huntington's disease, 151–152, 306–307
- independent oversight and regulation of clinics, 312
- informed consent issue, 319–320
- liver disease, 159–160, 164–166
- lupus, 192
- multiple sclerosis, 190, 308
- Niemann-Pick Disease, 152–153, 335
- obstacles to, 295–302
- Parkinson's disease, 153–156, 306–307, 335
- patient testimonials, 317–318
- replacement tissues, 305–306
- reversing retinal degeneration, 308–309
- risks and side effects, 315–317
- scams and charlatans, 320–321
- spinal cord injuries, 67, 156–157, 194–195, 306
- as stem cell purpose, 19
- stroke, 157–158, 307
- regulation
 - about, 251–252
 - drug therapy, 178–179
 - federal role, 251–252, 253–256, 258–261, 288
 - human subjects, research on, 259–261
 - scientific community's views, 261
 - state role, 228–229, 264–265
 - stem cell treatment clinics, 312
- relapse, preventing disease, 211
- religious positions on stem cell research, 235–238, 240, 244, 247
- replacement, cell, 19, 24
- replacement tissues, 305–306
- reproductive cloning
 - defined, 336
 - legal restrictions on, 263, 265
 - SCNT, 89–91, 108–114, 242, 337
- reproductive sources for pluripotent cell types, 97
- reproductive system, 32
- reprogramming, defined, 336
- research embryos, 241–242, 288–289
- research model, 109
- research on stem cells
 - about, 87
 - animals, working with, 12–15, 142
 - clinical trials
 - ALS treatments, 146, 147–149
 - Alzheimer's disease, 140–142
 - animal treatment potential for humans, 196
 - Batten Disease, 150
 - cancer, 189
 - challenges of, 197–199
 - cost of, 301
 - defined, 330
 - design, 302
 - double-blind, 292, 331
 - drug development, relationship to, 174–179

research on stem cells (*continued*)

- heart disease, 162–163, 301–302
 - NIH registry, 326
 - Parkinson's disease, 156–157
 - spinal cord injury, 67, 157, 194–195
 - controversy overview, 87–88
 - current efforts, 66–67
 - drug therapies, relationship to, 179–180, 290–291, 304–305
 - embryonic stem cells, 65–68, 253–254, 293, 294
 - ethical issues. *See* ethical issues
 - funding and profits. *See* funding and profits
 - future directions, 67–68
 - goals, 19, 247–248
 - history
 - about, 37
 - cloning animals, 50
 - genetic controls in cells, 41–46
 - regeneration of body parts, 38–40
 - transplanting organs and tissues, 46–49
 - in vitro fertilization, 49–50
 - human cloning, compared to, 291
 - identifying stem cells, 18–19
 - introduction, 1–7
 - laws and policies. *See* laws and policies
 - mixed-and-matched cells. *See* mixing and matching cells
 - nuclear transfer techniques
 - ANT (altered nuclear transfer), 91, 242, 329
 - defined, 88
 - embryo development, 91–93
 - SCNT (somatic cell nuclear transfer), 89–91, 108–114, 242, 337
 - patents and licenses, 280–281
 - pluripotent cell generation, 93–96
 - politics of, 262–264
 - resources list, 323–328
 - status and public interest, 11
 - treatments from. *See* treatments
 - unanswered questions, 19–20
- resources list, 323–328
- respiratory system, 32
- retina, 308
- retinal degeneration, reversing, 308–309

- ribonucleic acid (RNA), 25, 42, 336
- Rilutek, 146
- risk-benefit profile, 172
- risks and side effects of treatment, 315–317
- RNA (ribonucleic acid), 25, 42, 336
- RNA viruses, 42
- Rockefeller Institute of Government (Web site), 272
- rods (photoreceptor cell), 309
- Roe v. Wade* abortion case, 234, 253, 262
- rogue cells, 15
- Roman Catholic viewpoint, 235, 236, 240, 247



- safety issues
 - clinical trials, 197–198
 - drug therapy, 176–178
 - regulation, 258–259
 - stem cell treatment, 300–301
- sarcoma, 131
- Schwann cell, 24, 336
- Science Daily (Web site), 328
- scientific community. *See also* research on stem cells
 - on ethical issues, 243, 244–245, 246, 265
 - goals of stem cell research, 247–248
 - National Academy of Sciences, 243, 323–324
 - on regulation, 261
 - self-monitoring efforts through professional societies, 267–268
 - stem cell research efforts, 65–68
- SCNT (somatic cell nuclear transfer), 89–91, 108–114, 242, 337
- self-renewing capacity of stem cells, 13, 35
- seminal vesicle, 32
- sensory axon, 23
- sensory neuron, 23, 336
- shrinking of brain tissue in Alzheimer's, 139
- SIDS (sudden infant death syndrome), 244–245
- signal types, cell communication, 29

- single twin, 106
- single-blind trial, 177
- single-celled organism, 25
- sizing cells, 23–24
- skeletal muscle, 32, 82
- skeletal system, 32
- skin, 14–15, 40, 83, 186–187
- smooth muscle, 32
- social justice imperative in stem cell research, 268
- soft inheritance in heredity, 41
- somatic cell nuclear transfer (SCNT), 89–91, 108–114, 242, 337
- somatic stem cells, 89, 329, 337. *See also* adult stem cells
- specialization, cell, 14, 16
- speech therapy for ALS, 146
- Spemann, Hans (researcher), 50
- spermagonial stem cell, 97
- spinal cord injuries, 67, 156–157, 194–195, 306
- spinal muscular atrophy, 66
- spleen colonies, 13
- sporadic anemia, 329
- sporadic disease, 141, 337
- state laws and regulations, 228–229, 264–265
- statins, 141, 172
- Stem Cell Research News (Web site), 328
- stem cells
 - adult. *See* adult stem cells
 - amniotic, 329
 - banking
 - about, 221
 - choosing a bank, 227–230
 - cord-blood banking process, 222–227
 - depositing into, 224–226
 - future of, 230
 - private compared to public storage, 223–224, 225
 - problems with, 226–227
 - blood-forming, 72, 78, 202, 333
 - from bone marrow, 13–14, 78–81, 185, 203–204
 - brain, 81–82, 143
 - cancer stem cells, 96–97, 129–135
 - compared to other cells, 33–35
 - cultivating for use, 296–297
 - culturing process, 13
 - defined, 33, 72, 337
 - directing cell specialization, 62–63
 - elimination, 297–298
 - embryonic. *See* embryonic stem cells
 - endothelial, 78
 - engineering of, 98–99
 - fetuses, relationship to, 97, 255, 287–288
 - finding in tissue, 77–84
 - in gene therapy, 209
 - germ layers
 - defined, 333
 - ectoderm, 56, 331
 - embryoid bodies, 62, 332
 - endoderm, 56, 282, 332
 - mesoderm, 56, 334
 - growing pure, 64–65
 - harvesting from bloodstream, 204–205
 - heart, 82
 - hematopoietic, 72, 78, 202, 333
 - identifying, 17, 46–47
 - intestinal, 82
 - lung, 83
 - mesenchymal, 49, 78, 81, 88, 334
 - multipotent capability, 61, 71, 329, 334
 - myths about, 287–294
 - neuronal, 142, 150, 335
 - pancreatic, 83
 - pluripotent, 61, 87, 96–99, 333, 336
 - properties, 16–18
 - pros and cons of sources, 205–206
 - replacement tissues, 19
 - research on. *See* research on stem cells
 - self-renewing, 13
 - skin, 83
 - somatic, 89–91, 108–114, 242, 329, 337
 - spermagonial, 97
 - totipotent, 61, 338
 - tracking, 299–300
 - transporting, 299–300
 - treatments for. *See* treatments from tumors, 96–97
 - “Stembook” (Web site), 325
 - stent, 160

sterile, defined, 214
 stomach, properties of, 30
 storing stem cells
 about, 221
 choosing a bank, 227–230
 cord-blood banking process, 222–227
 depositing into, 224–226
 future of, 230
 private compared to public storage,
 223–224, 225
 problems with, 226–227
 straight face test, 240
 striatum, 152
 stroke, 157–158, 307
 stromal cells, 63
 subculturing stem cells, 60
 substantia nigra, 152
 Sudden Infant Death Syndrome (SIDS),
 244–245
 suicide, cell, 126
 superoxide dismutase 1, 147
 symmetric cell division, 22, 337
 synapses, 24, 329, 330, 337
 syngeneic transplant, 206, 207
 synthesis, cell, 22, 337

• T •

tactile signals in cell communication, 29
 Tagliacozzi, Gaspare (plastic surgeon),
 46, 48
 Taoism, 20
 teratocarcinoma, 96
 teratoma, 18, 96, 301, 337
 terminally differentiated cell, 130, 337
 testimonials, patient, 317–318
 therapeutic cloning, 108–109, 111, 337
 Thomson, James (researcher), 1, 241, 262
 Till, James (researcher), 13–14, 46, 47, 79
 tissue stem cells, 33, 71, 72, 73, 329. *See*
 also adult stem cells
 tissue type, 20, 209
 tissues and organs, building, 29–33
 totipotent stem cells, 61, 338
 trachea, 32

transcription factors, 19
 transdifferentiation, 17–18, 338
 translational research, 256, 338
 transplants
 about, 201–202
 allogeneic, 206, 207
 appropriateness, 202
 autologous, 186, 206, 207
 bone marrow, 185
 challenges of, 203–211
 chimera complications, 107
 current state of practice, 218–219
 donating organs and tissues for, 206–210,
 215–218
 graft-versus-host disease
 controlling, 211, 304
 defined, 333
 donor-recipient match for transplants,
 relationship to, 206
 function in transplants, 48, 185
 history, 46–49
 immune response, overcoming, 46–47,
 48–49, 210–211
 stem cell role in, 49, 203–206, 211–215
 syngeneic, 206, 207
 treatments
 adult stem cell successes, 292–293
 ALS (Lou Gehrig’s disease), 66, 107,
 145–149, 306–307, 329
 Alzheimer’s disease, 139, 140–144
 animal treatments, applying
 to humans, 196
 assessment of, 187–192, 312–313, 317
 Batten Disease, 149–150, 195
 bone marrow transplants
 for leukemia, 185
 cancer
 history of treatment attempts, 123–124
 treatments, 15, 130–131, 134–135,
 187–188, 212, 303–304
 cerebral palsy, 150–151
 development of, 313–314
 diabetes, 166–169, 191–192, 309–310
 drug therapies
 about, 171

- ALS (Lou Gehrig's disease), 107, 146–149
- Alzheimer's disease, 139, 141–143
- cancer treatment, 130–131, 134, 135
- clinical trials' role, 174–179
- cost of development, 174–179
- development process, 171–179
- genetic origins for response differences, 44
- Huntington's disease, 152
- for immune-suppression in transplant cases, 46–47, 48–49, 210–211
- insulin therapy using cloning technique, 110
- multiple sclerosis, 190
- Niemann-Pick disease, 153
- Parkinson's disease, 154, 155, 156
- pros and cons of current, 172–174
- regulation of, 178–179
- safety and effectiveness, 176–178
- stem cell role in, 68, 111, 179–180, 278–279, 290–291, 304–305
- tolerance issue, 173
- experimental, 314–315
- expert opinions, 319
- grafting skin to treat burns, 186–187
- heart disease
- challenges with stem cells, 163–164
 - clinical trials involving stem cells, 162–163, 189–190, 301–302
 - current treatment options, 160–161
 - stem cell treatment, 161–162, 189–190, 309
- hidden costs, 318–319
- Huntington's disease, 151–152, 306–307
- independent oversight and regulation of clinics, 312
- informed consent issue, 319–320
- liver disease, 159–160, 164–166
- lupus, 192
- multiple sclerosis, 190, 308
- Niemann-Pick Disease, 152–153, 335
- obstacles to, 295–302
- Parkinson's disease, 153–156, 306–307, 335
- patient testimonials, 317–318
- replacement tissues, 305–306
- reversing retinal degeneration, 308–309
- risks and side effects, 315–317
- scams and charlatans, 321–322
- spinal cord injuries, 67, 156–157, 194–195, 306
- as stem cell purpose, 19
 - stroke, 157–158, 307
- Trembley, Abraham (zoologist), 39
- trophectoderm, 91, 330, 338
- tubal pregnancy, 244
- tumor. *See also* cancer
- benign, 128, 301
 - collecting stem cells from, 96–97
 - teratoma, 18, 96, 301, 337
- tumor suppressor genes, 126, 338
- Tuskegee Syphilis Study, 259
- Type 1 diabetes, 167–168, 191–192
- Type 2 diabetes, 168–169
- Type A, Niemann-Pick Disease, 152
- Type B, Niemann-Pick Disease, 152
- Type C, Niemann-Pick Disease, 153

• U •

- umbilical cord blood
- about, 84–85
 - banking of
 - about, 221
 - banking process, 222–227
 - choosing a bank, 227–230
 - depositing into, 224–226
 - private compared to public storage, 223–224, 225
 - problems with, 226–227
 - defined, 331, 338
 - medical uses, 221–222
 - as stem cell source, 205
- undifferentiated cells, 338. *See also* stem cells
- Unitarian Universalist Association's viewpoint, 236
- United Church of Christ's viewpoint, 236
- United Network for Organ Sharing (UNOS) (Web site), 215

United States Patent and Trademark Office (USPTO), 279–280

University of California–San Diego Stem Cell Initiative (Web site), 325–326

ureter, 32

urethra, 32

uterus, 338

utility patent, 280

• U •

ventricle, 81

venture capital, 278

vesicle, 26

viability, fetal, 57

• W •

WARF patents, 281–282

Warnock Commission viewpoint, 238

Watson, James (researcher), 43

web sites

AABB, 229

American Society of Reproductive Medicine, 327

Be The Match Foundation, 217, 326

Clonaid, 113

FACT, 229

Harvard Stem Cell Institute, 325

ISO, 229

ISSCR, 266, 267–268, 325

Medical News Today, 328

National Academies, 267, 323–324

National Academy of Sciences, 243, 323–324

National Bone Marrow Program, 326

National Cancer Institute, 324

National Heart, Lung, and Blood Institute, 324

National Human Genome Research Institute, 324

National Institute of Diabetes and Digestive and Kidney Diseases, 324

National Institute of Neurological Disorders and Stroke, 324

National Institutes of Health (NIH), 324

National Marrow Donor Program, 215, 217

Nobel Foundation, 327

President's Council on Bioethics, 328

Rockefeller Institute of Government, 272

Science Daily, 328

Stem Cell Research News, 328

“Stembook,” 325

University of California–San Diego Stem Cell Initiative, 325–326

UNOS, 215

Weismann, August (biologist), 41, 50

Weissman, Irving (researcher), 46

white blood cells, 204

Wilkins, Maurice (researcher), 43

Willowbrook State School

hepatitis study, 260

Witte, Owen (researcher), 1

• Y •

Yamanaka, Shinya (researcher), 98

yeast compared to human cells, 12

yellow marrow, 204

• Z •

zygote, 55, 338

